Sebetralstat is under clinical development by Kalvista Pharmaceuticals and currently in Phase III for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). According to GlobalData, Phase III drugs for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Sebetralstat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sebetralstat overview
Sebetralstat (KVD-900) is under development for the treatment of hereditary angioedema. The drug candidate is administered through the oral route in the form of the tablet. It acts by targeting plasma kallikrein.
Kalvista Pharmaceuticals overview
Kalvista Pharmaceuticals (Kalvista) is a Biotech company. It focusses on the discovery, development, and commercialization of small molecule protease inhibitors. Its products include KVD824 and KVD001, a plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE. The company’s product candidates are inhibitors of plasma kallikrein, which is being developed for hereditary angioedema (HAE) and diabetic macular edema (DME) indications. Kalvista is also progressing additional oral candidates towards regulatory preclinical studies. The company has its operations in the US and the UK. Kalvista is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Sebetralstat’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - Sebetralstat in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)
Premium Insights
The gold standard of business intelligence.
